RE: Profit warnings come in 313 Apr 2021 15:34
So what's new? The company already stated that in the recent RNS, hence the 40% drop in shareprice.
Whoever wanted to sell have sold out by now and new group of investors & traders (and hopefully Institutional investors) currently buying and expecting international expansion & new contracts going forward.
According to our company's chairman this morning in Sourcebio results:
"With peak demand occurring in the seasonally affected first quarters of 2021 and 2022. Although we expect testing volumes to decline after 2021, we expect a continued need for testing in 2023 and 2024 as the disease enters a more endemic phase". Airports, airlines, cruise lines and hotels are already looking to establish testing services for passengers and guests. Similarly, the sports and entertainment industries are also building on-site testing capabilities and tests are expected to continue to be sold in leading high street pharmacy outlets."
https://www.londonstockexchange.com/news-article/SBI/final-results/14934283